Wild gorillas carriers of a SIV virus close to the AIDS virusNovember 14, 2006
Some months ago, the team of Martine Peeters, director of research at IRD, and Eric Delaporte, director of the mixed research unit UMR 145 jointly involving the IRD and the University of Montpellier 1, showed the chimpanzee subspecies living in the Congo Basin (2) to be the reservoir of HIV-1 virus group M, the source of the world pandemic and that of another, very rare variant, HIV-1 group N. However, the reservoir of the third HIV-1 group, group O which infects humans (3), remained unidentified up to now.
This team announces, in an article in the journal Nature, the discovery of a simian immunodeficiency virus (SIV) infection in wild gorillas. Samples of faeces collected from different communities of gorillas found in the remotest areas of the Cameroon tropical forest were found to contain antibodies against this virus, called SIVgor. The genetic characteristics of the virus were present again in three gorillas living more than 400 km apart. Phylogenetic analysis of SIVgor showed it to be related to HIV-1 group O found in humans, essentially in Cameroon and in neighbouring countries.
This discovery of an HIV-1 related virus in wild gorillas does not, however, call into question the fact that chimpanzees are the primary reservoir of SIV/HIV viruses that crop up again in gorillas and in humans. As Martine Peeters of the IRD says, "the viruses of groups M and N are, very clearly, the consequence of inter-species transmission from chimpanzee to humans, whereas the origin of HIV-1 group O is less apparent. It cannot be excluded that chimpanzees infected by HIV-1 group O might have contaminated humans and the gorilla independently, or that the gorilla, having been contaminated by the chimpanzee, might have contaminated humans".
This work thus opens up a Pandora's box on the questions and speculations concerning the ability of these viruses to cross over from one species to another. The main challenges facing these teams for future work will be determination of the prevalence, the geographical distribution and biology of SIV infections in these great apes, not forgetting the question of how the gorillas were contaminated. This last point remains a mystery,considered as rare.
1. UMR 145: Fran Van Heuverswijn, Cecile Neel, Florian Liegeois, Christelle Butel, Eric Delaporte and Martine Peeters jointly involving the IRD and the University of Montpellier1 University of Alabama (Beatrice Hahn and her colleagues), University of Nottingham (Paul Sharp and his colleagues) PRESICA Project of Cameroon headed by Eitel Mpoudi-Ngole.
2. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Mpoudi Ngole E, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH. Chimpanzee Reservoirs of Pandemic and Nonpandemic HIV-1. Science. 2006 , 313 : 523-6
3. Scientists have known for a long time that the Aids virus shows a very strong genetic variability. Two main types of the virus exist: HIV 1 and HIV 2. HIV 1, the most widely spread in the world, embraces three groups (M, N,O) which manifest different genetic characteristics. Within group M, the most frequent, still 9 further subtypes can be distinguished (A, B, C, D, F, G, H, J, K), genetically close yet distinct.
Institut de Recherche Pour le Développement
Related Hiv-1 Current Events and Hiv-1 News Articles
New model finds HIV acute phase infectivity may be lower than previously estimated
Previous calculations may have overestimated the importance of HIV transmission from recently infected individuals ("acute phase infectivity") in driving HIV epidemics, according to an article published by Steve Bellan of The University of Texas at Austin, and colleagues in this week's PLOS Medicine.
Common herpes medication reduces HIV-1 levels, independent of herpes infection
Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels -- even when patients do not have herpes.
Postoperative mortality rates low among patients with HIV prescribed ART
ostoperative mortality rates were low among patients infected with the human immunodeficiency virus (HIV) who are receiving antiretroviral therapy (ART), and those mortality rates were influenced as much by age and poor nutritional status as CD4 cell counts.
Genetically engineered antibody-based molecules show enhanced HIV-fighting abilities
Capitalizing on a new insight into HIV's strategy for evading antibodies--proteins produced by the immune system to identify and wipe out invading objects such as viruses--Caltech researchers have developed antibody-based molecules that are more than 100 times better than our bodies' own defenses at binding to and neutralizing HIV, when tested in vitro.
LSU Health New Orleans identifies toxic Ebola protein fragment
William Gallaher, PhD, Emeritus Professor of Microbiology, Immunology & Parasitology at LSU Health New Orleans School of Medicine, has discovered a fragment of an Ebola virus protein that is toxic to cells and may contribute to infection and illness.
Progress toward an HIV cure highlighted in special issue of AIDS Research and Human Retroviruses
A cure for HIV/AIDS is the ultimate goal of rapidly advancing research involving diverse and innovative approaches.
Dolutegravir/abacavir/lamivudine: Considerable added benefit for some adults with HIV
Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age.
CWRU researchers discover byproducts from bacteria awaken dormant T-cells and HIV viruses
Dental and medical researchers from Case Western Reserve University found another reason to treat periodontal disease as soon as possible.
Molecules seen binding to HIV-1's protective capsule, blocking infection
Imagine a suitcase on a bumpy ride. With enough jostling it opens, spilling clothes everywhere. Similarly awkward, the suitcase locks may jam and not open at the destination.
Cell-associated HIV mucosal transmission: The neglected pathway
Dr. Deborah Anderson from Boston University School of Medicine (BUSM) and her colleagues are challenging dogma about the transmission of the human immunodeficiency virus type 1 (HIV-1).
More Hiv-1 Current Events and Hiv-1 News Articles